1. Home
  2. TKO vs BIIB Comparison

TKO vs BIIB Comparison

Compare TKO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TKO
  • BIIB
  • Stock Information
  • Founded
  • TKO 1980
  • BIIB 1978
  • Country
  • TKO United States
  • BIIB United States
  • Employees
  • TKO N/A
  • BIIB N/A
  • Industry
  • TKO
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • TKO
  • BIIB Health Care
  • Exchange
  • TKO Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • TKO 14.5B
  • BIIB 24.2B
  • IPO Year
  • TKO N/A
  • BIIB 1991
  • Fundamental
  • Price
  • TKO $184.25
  • BIIB $168.52
  • Analyst Decision
  • TKO Strong Buy
  • BIIB Buy
  • Analyst Count
  • TKO 17
  • BIIB 24
  • Target Price
  • TKO $213.69
  • BIIB $174.62
  • AVG Volume (30 Days)
  • TKO 1.2M
  • BIIB 1.8M
  • Earning Date
  • TKO 11-05-2025
  • BIIB 10-30-2025
  • Dividend Yield
  • TKO 1.65%
  • BIIB N/A
  • EPS Growth
  • TKO N/A
  • BIIB N/A
  • EPS
  • TKO 1.85
  • BIIB 10.97
  • Revenue
  • TKO $2,545,175,000.00
  • BIIB $10,065,900,000.00
  • Revenue This Year
  • TKO $69.06
  • BIIB $2.97
  • Revenue Next Year
  • TKO $27.63
  • BIIB N/A
  • P/E Ratio
  • TKO $99.24
  • BIIB $15.27
  • Revenue Growth
  • TKO N/A
  • BIIB 4.77
  • 52 Week Low
  • TKO $115.77
  • BIIB $110.04
  • 52 Week High
  • TKO $212.49
  • BIIB $175.86
  • Technical
  • Relative Strength Index (RSI)
  • TKO 44.33
  • BIIB 74.64
  • Support Level
  • TKO $177.12
  • BIIB $151.83
  • Resistance Level
  • TKO $187.01
  • BIIB $157.79
  • Average True Range (ATR)
  • TKO 4.46
  • BIIB 5.59
  • MACD
  • TKO -0.10
  • BIIB 1.37
  • Stochastic Oscillator
  • TKO 50.20
  • BIIB 95.37

About TKO TKO Group Holdings Inc.

TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: